公开(公告)号：US20170240548A1

公开(公告)日：2017-08-24

申请号：US15435137

申请日：2017-02-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Patrick LEE ,  Peichao LU ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D491/147 ,  A61K31/4375

CPC classification number: C07D471/14 ,  A61K31/4375 ,  C07D217/08 ,  C07D491/14 ,  C07D491/147

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20210130302A1

公开(公告)日：2021-05-06

申请号：US17030540

申请日：2020-09-24

Applicant: Novartis AG ,  Gilead Sciences, Inc.

Inventor： Zef KONST ,  Yipin LU ,  Robert Joseph MOREAU ,  Naomi Samadara RAJAPAKSA ,  Galen SHEARN-NANCE ,  David Charles TULLY ,  Michael Robert TURNER ,  Joseph Michael YOUNG ,  Qian ZHAO ,  Britton K. CORKEY ,  Samuel E. METOBO

IPC: C07D243/10

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

公开(公告)号：US20190300530A1

公开(公告)日：2019-10-03

申请号：US16383382

申请日：2019-04-12

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D401/12 ,  C07D491/16 ,  A61P31/12 ,  A61K45/06 ,  C07D471/22 ,  A61K31/4985 ,  C07D405/12

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20180030053A1

公开(公告)日：2018-02-01

申请号：US15782722

申请日：2017-10-12

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Patrick LEE ,  Peichao LU ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D491/147 ,  A61K31/4375

CPC classification number: C07D471/14 ,  A61K31/4375 ,  C07D217/08 ,  C07D491/14 ,  C07D491/147

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20200270265A1

公开(公告)日：2020-08-27

申请号：US15999664

申请日：2017-02-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Xianming JIN ,  Patrick LEE ,  Peichao LU ,  Joseph Michael YOUNG

IPC: C07D491/147 ,  C07D471/04 ,  C07D519/00 ,  A61P31/20

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20200270252A1

公开(公告)日：2020-08-27

申请号：US16808985

申请日：2020-03-04

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D405/12 ,  A61P31/12 ,  C07D491/16 ,  C07D401/12 ,  A61K45/06 ,  A61K31/4985 ,  C07D471/22

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20210346377A1

公开(公告)日：2021-11-11

申请号：US16956527

申请日：2018-12-19

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Xianming JIN ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: A61K31/4985 ,  C07D471/14 ,  A01N43/90 ,  A61K45/06 ,  A61K47/60 ,  A61K38/21 ,  A61P31/20

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20180312507A1

公开(公告)日：2018-11-01

申请号：US15965172

申请日：2018-04-27

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D405/12 ,  C07D401/12 ,  C07D491/16 ,  A61P31/12

CPC classification number: C07D471/14 ,  A61K31/4985 ,  A61K45/06 ,  A61P31/12 ,  C07D401/12 ,  C07D405/12 ,  C07D471/22 ,  C07D491/16

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.